Supplemental Figure 1 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins

2026 Open access

Read full text
Authors: Christopher J. Nirschl, Kulandayan K. Subramanian, Heather R. Brodkin, Celesztina Domonkos, Connor J. Dwyer, Daniel J. Hicklin, RANDI E. ISAACS, Nesreen S. Ismail, Julie LePrevost, Yuka Lewis, Kristin R. Morris, Cynthia Seidel‐Dugan
+5 more Zoe Steuert, Jenna M. Sullivan, Sameer S. Chopra, Andrés Salmerón, William M. Winston
DOI: 10.1158/2326-6066.31484134
Cited by: 0

Fields of Study & Subjects

T-cell and B-cell Immunology Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

Publication details

Publication date
4 March 2026
Language
EN